Home > News > APP Announces Positive Results of Intra-Arterial ABI-007
June 4th, 2003
APP Announces Positive Results of Intra-Arterial ABI-007
At the American Society of Clinical Oncology annual meeting held in Chicago, Illinois, American Pharmaceutical Partners, Inc. said that investigators from the Insituto dei Tumori in Milan, Italy, reported on their experience in 108 patients receiving high dose ABI-007, a novel cremophor-free protein engineered nanoparticle paclitaxel, by the intra-arterial route.
Non-Toxic Nanocatalysts Open New Window for Significant Decrease in Reaction Process October 19th, 2014
European Commission opens the gate towards the implementation of Nanomedicine Translation Hub October 16th, 2014
Nanodevices for clinical diagnostic with potential for the international market: The development is based on optical principles and provides precision and allows saving vital time for the patient October 15th, 2014
Tuning light to kill deep cancer tumors: Nanoparticles developed at UMass Medical School advance potential clinical application for photodynamic therapy October 15th, 2014